Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement?

Area of Science:

• Hepatobiliary oncology
• Interventional radiology
• Health services research

Background:

• Transarterial chemoembolization (TACE) is a primary oncologic therapy for hepatocellular carcinoma (HCC) per American Association for the Study of Liver Diseases (AASLD) guidelines.
• The 2005 and 2011 AASLD guidelines aimed to standardize HCC management, impacting TACE utilization in clinical practice.

Purpose of the Study:

• To evaluate the impact of AASLD criteria for hepatocellular carcinoma (HCC) management on the community practice of Transarterial chemoembolization (TACE).
• To assess survival outcomes in HCC patients treated with TACE based on their tumor characteristics relative to AASLD criteria.

Main Methods:

• Analysis of clinical, demographic, and mortality data from the 2012 Surveillance, Epidemiology, and End Results (SEER) Medicare database for HCC patients.
• Utilized propensity score survival analysis to compare outcomes among patients whose tumor characteristics were less than, met, or exceeded AASLD criteria for TACE.

Main Results:

• The proportion of HCC patients receiving TACE who met AASLD criteria increased post-2005 guidelines.
• Up to 17% of TACE-treated patients had characteristics below AASLD criteria, potentially missing curative options.
• Propensity score matching showed the greatest survival benefit for patients meeting AASLD criteria (HR 0.42), with significant advantages also seen for those exceeding criteria.

Conclusions:

• AASLD criteria effectively identify HCC patients who maximally benefit from TACE.
• HCC patients with tumor characteristics beyond AASLD criteria also experience significant survival advantages with TACE.
• Further research is needed to refine referral patterns and optimize TACE use for unresectable HCC.